Evidence map›Paper›PMID 20705106›Full record

ArticleAntiviral research2010

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Meital Gal-Tanamy, Romy Zemel, Larissa Bachmatov, Rohit K Jangra, Assaf Shapira, Rodrigo A Villanueva, Minkyung Yi, Stanley M Lemon, Itai Benhar, Ran Tur-Kaspa

Abstract read
In one paragraph

Article in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Meital Gal-TanamyMolecular Hepatology Research Laboratory, Felsenstein Medical Research Center, Sackler School of Medicine, Tel-Aviv University, Petah Tikva, Israel.
Romy Zemel
Larissa Bachmatov
Rohit K Jangra
Assaf Shapira
Rodrigo A Villanueva
Minkyung Yi
Stanley M Lemon
Itai Benhar
Ran Tur-Kaspa
Tel Aviv University · ILThe University of Texas Medical Branch at Galveston · USRabin Medical Center · IL

Funding

Virus-Host Interactions in Hepatitis C Virus (HCV) InfectionsU19AI040035 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI LEMON, STANLEY M. · 1996 to 2009
$12.0M
NIAID NIH HHS N01 AI025488NIAID NIH HHS U19 AI040035NIAID NIH HHS U19-AI40035
6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and a serious threat to human health. The HCV NS3/4A serine protease is necessary for viral replication and innate immune evasion, and represents a well-validated target for specific antiviral therapy. We previously reported the isolation of single-chain antibodies (scFvs) that inhibit NS3/4A protease activity in vitro. Expressed intracellularly (intrabodies), these scFvs blocked NS3-mediated proliferation of NS3-transfected cells. Here we show that anti-NS3 scFvs suppress HCV RNA replication when expressed intracellularly in Huh7 hepatoma cells bearing either subgenomic or genome-length HCV RNA replicons. The expression of intrabodies directed against NS3 inhibited the autonomous amplification of HCV replicons resistant to small-molecule inhibitors of the NS3/4A protease, and replicons derived from different HCV genotypes. The combination of intrabodies and interferon-α had an additive inhibitory effect on RNA replication in the replicon model. Intrabody expression also inhibited production of infectious HCV in a cell culture system. The NS3 protease activity was inhibited by the intrabodies in NS3-expressing cells. In contrast, cell-free synthesis of HCV RNA by preformed replicase complexes was not inhibited by intrabodies, suggesting that the major mode of inhibition of viral replication is inhibition of NS3/4A protease activity and subsequent suppression of viral polyprotein processing.

Indexed as

HepacivirusAntibodies, ViralAntiviral AgentsCell LineDEAD-box RNA HelicasesDrug Evaluation, PreclinicalDrug Therapy, CombinationEnzyme-Linked Immunosorbent AssayFluorescent Antibody TechniqueHumansInterferon-alphaNucleoside-TriphosphatasePlasmidsPolymerase Chain ReactionPolyproteinsProtease InhibitorsAntibodies, ViralAntiviral AgentsDEAD-box RNA HelicasesInterferon-alphaNS3 protein, hepatitis C virusNucleoside-TriphosphatasePolyproteinsProtease InhibitorsRNA-Dependent RNA PolymeraseRNA, ViralSerine EndopeptidasesSingle-Chain AntibodiesViral Nonstructural ProteinsViral Proteases

Identifiers

PMID20705106
PMCPMC4418563
OpenAlexW2042818970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.